Pacific Edge mulls what analysts call serious Medicare decision

Dual-listed cancer diagnostics company Pacific Edge is assessing the implications of Novitas’s decision its Cxbladder tests will not be covered by US national health insurance provider Medicare and expects to provide a full update before trading opens on Wednesday morning. And analysts are nowRead More